Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 6/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19480157 | 0.91 | ACACB (0.43) | TLR8TLR7ACACBGPR119KDM5A | |
| SCHEMBL19473347 | 0.88 | PRMT5 (0.49) | TLR8TLR7ACACBKDM5APRMT5 | |
| SCHEMBL17572982 | 0.84 | NOS3 (0.51) | ACACBGPR119PRMT5 | |
| SCHEMBL19473350 | 0.82 | NAMPT (0.48) | ACACBGPR119 | |
| SCHEMBL17559414 | 0.82 | PRMT5 (0.46) | GPR119PRMT5HRH3 | |
| SCHEMBL19473346 | 0.81 | GPR119 (0.43) | ACACBGPR119 | |
| SCHEMBL18672932 | 0.81 | TLR9 (0.43) | TLR8TLR7ACACBHRH3 | |
| SCHEMBL20890032 | 0.80 | LOX (0.45) | TLR8TLR7ACACB | |
| SCHEMBL3604247 | 0.80 | GPR119 (0.52) | GPR119 | |
| SCHEMBL3256744 | 0.80 | ACACB (0.43) | ACACBGPR119KDM5APRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | TLR8 4821/4885TLR7 4328/4885ACACB 4035/4885 |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | TLR8 4847/4885TLR7 4458/4885ACACB 3901/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | TLR8 4847/4885TLR7 4458/4885ACACB 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.